MarketBeat
09 May 2026, 09:07 UTC · 18w ago
Verdict
Headline takes no side. We score ZYME +0.40 across five claims — moderately bullish.
+0.40moderately bullish
More positive than 63% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
Zymeworks anticipates near-term milestone payments of $250 million from Jazz and $50 million from BeOne contingent on potential approvals of zanidatamab in the U.S. and China.
So whatA combined $300 million in anticipated milestone payments represents a highly material catalyst for a company with a $44.2 million net loss and significant upside risk conversion if approvals are achieved.
More positive than 99% of claims this week
Zymeworks reported a Q1 net loss of $44.2 million, widening significantly from a $22.6 million loss in the prior-year period due to the absence of prior-year milestone revenue.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
So whatA near-doubling of net losses highlights current cash burn and revenue dependency on non-recurring milestones, negatively impacting near-term profitability metrics.
More negative than 92% of claims this week
ZW191 demonstrated a confirmed overall response rate of 61% in the clinically relevant dose range for heavily pretreated platinum-resistant ovarian cancer patients.
More positive than 86% of claims this week
Zymeworks ended the quarter with $403.8 million in cash resources, up from $270.6 million at year-end 2025.
So whatA substantial increase in cash resources significantly extends the company's runway and de-risks the balance sheet against operational cash burn.
More positive than 76% of claims this week
Zymeworks has repurchased approximately 8.3 million shares, representing more than 10% of common shares outstanding, deploying $155.8 million at a weighted average price of $18.70.
More positive than 70% of claims this week
Which stocks this story touches
More positive than 63% of ticker scores this week
Despite a wider quarterly loss and revenue decline, the company has strong cash reserves, an aggressive share repurchase program, and promising pipeline data for ZW191 and its pan-RAS ADC platform.
More positive than 56% of ticker scores this week
The company is partnered on zanidatamab, which has upcoming regulatory catalysts and potential for commercialization.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1d ago
[a_to_b] Jazz Pharmaceuticals is expected to make milestone payments to Zymeworks upon U.S. approval of zanidatamab.
+11.8%
Price agrees with the score
$26.70 vs $23.89 close before publication (May 8) · not market-adjusted
ZYME chart →
